Superworth

Vir Biotechnology profit margin VIR

Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.

Net margin, 12 months
−83.0%
Operating margin, 12 months
−92.4%
Peer median
22.2%

Over the twelve months to Jun 30, 2026, Vir Biotechnology kept −83.0% of its revenue as net profit, with an operating margin of −92.4%.

The median for 10 biotech stocks of a similar size is 22.2%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025n/an/a100.0%
FY2024n/an/a98.9%
FY2023n/an/a96.8%
FY202231.9%51.6%90.9%
FY202148.3%38.4%94.0%
FY2020n/an/an/a
FY2019n/an/an/a
FY2018n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−83.0%n/a−92.4%
Q1 FY26n/an/an/a
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Biotechnology nearest Vir Biotechnology's size, closest first, today.

CompanyProfit margin
VIRVir Biotechnology−83.0%
VCELVericel7.9%
ADMAAdma Biologics33.0%
MGTXMeiraGTx19.9%
KRYSKrystal Biotech54.8%
RGENRepligen5.3%
TECHBIO-TECHNE15.0%
HALOHalozyme Therapeutics24.9%
NBIXNeurocrine Biosciences20.9%
PLXProtalix BioTherapeutics23.5%
EXELExelixis35.3%
Peer median22.2%

Where Vir Biotechnology ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Vir Biotechnology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.